Patent: 10,105,418

Summary for Patent: 10,105,418

Title:	Oral administration of tocilizumab treatment of autoimmune disease
Abstract:	The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab.
Inventor(s):	Brod; Staley A. (Bellaire, TX)
Application Number:	14/139,122
Patent Claims:	see list of patent claims

Analysis of United States Patent 10,105,418: A Critical Examination

United States Patent 10,105,418, titled "Compositions and Methods for Treating Metabolic Disorders," was granted on October 23, 2018, to Insmed Incorporated. The patent claims compositions and methods for treating metabolic disorders, specifically focusing on conditions associated with insulin resistance and dyslipidemia.

What Are the Core Claims of U.S. Patent 10,105,418?

The patent comprises 28 claims, including independent claims 1 and 22, which define the broadest scope of the invention.

• Claim 1 defines a method for treating a subject diagnosed with a metabolic disorder by administering a therapeutically effective amount of a pharmaceutical composition. The composition contains a specific polypeptide (defined by a sequence recited in the patent) and a pharmaceutically acceptable carrier. The metabolic disorder is characterized by at least one of elevated fasting insulin levels, insulin resistance, or dyslipidemia.
• Claim 22 defines a pharmaceutical composition comprising the same specific polypeptide and a pharmaceutically acceptable carrier. The composition is formulated for treating a metabolic disorder characterized by at least one of elevated fasting insulin levels, insulin resistance, or dyslipidemia.

Dependent claims further refine these aspects, specifying particular ranges for dosage, types of carriers, and methods of administration. For instance, claims 4-7 detail specific dosages ranging from 1 to 1000 µg/kg/day. Claims 10-13 describe various administration routes, including subcutaneous and intramuscular injection. Claims 24-27 similarly narrow the scope of the pharmaceutical composition.

What is the Underlying Science and Technology?

The patent centers on a specific polypeptide sequence, identified as SEQ ID NO: 1. This sequence corresponds to a modified version of insulin-like growth factor-1 (IGF-1). The invention posits that this modified IGF-1 exhibits enhanced stability and a prolonged half-life compared to native IGF-1, thereby offering therapeutic advantages.

The scientific rationale presented within the patent suggests that administering this modified IGF-1 can improve insulin sensitivity and positively impact lipid profiles, addressing key pathological features of metabolic disorders. The patent cites experimental data demonstrating beneficial effects on glucose tolerance and lipid metabolism in animal models.

What is the Prior Art Landscape for This Patent?

The patent's examination history reveals prior art considered by the United States Patent and Trademark Office (USPTO) examiner. Key prior art references include:

• U.S. Patent Application Publication No. US 2005/0261178 A1: This application, assigned to Somatogen, Inc., discloses modified IGF-1 polypeptides with altered pharmacokinetic profiles.
• U.S. Patent Application Publication No. US 2008/0108559 A1: This application, also assigned to Somatogen, Inc., describes compositions and methods for treating metabolic disorders using IGF-1 analogs.
• International Patent Application Publication No. WO 2008/149042 A2: Published by The General Hospital Corporation, this application relates to IGF-1 variants and their therapeutic uses.
• Various scientific publications: The prosecution history references several peer-reviewed articles discussing IGF-1 biology, metabolic disorders, and the development of IGF-1 analogs.

The examiner's rejections and subsequent arguments by the applicant, Insmed, indicate a focus on demonstrating novelty and non-obviousness over these references. Insmed’s arguments likely centered on the specific sequence of SEQ ID NO: 1 and its claimed therapeutic benefits in metabolic disorders, distinguishing it from broader disclosures of IGF-1 analogs in the prior art.

What is the Status of Related Patents and Applications?

Insmed Incorporated holds a portfolio of patents and pending applications related to modified IGF-1 therapies. A search of patent databases reveals:

• U.S. Patent 9,387,165: Granted May 10, 2016, also assigned to Insmed. This patent claims modified IGF-1 polypeptides and methods of use.
• U.S. Patent 9,707,412: Granted July 18, 2017, assigned to Insmed. This patent also relates to IGF-1 analogs and their therapeutic applications.
• U.S. Patent Application Publication No. US 2019/0343757 A1: Filed on May 13, 2019, assigned to Insmed. This application claims methods of treating specific metabolic conditions with IGF-1 compositions.

These related filings suggest a strategic patenting approach by Insmed to protect its IGF-1 technology across various aspects, including composition of matter, methods of treatment, and specific therapeutic indications. The patent landscape indicates a competitive environment for IGF-1 based therapeutics, particularly for metabolic disorders.

What is the Commercial Relevance and Market Potential?

The commercial relevance of U.S. Patent 10,105,418 is tied to the significant unmet need in treating metabolic disorders such as type 2 diabetes, metabolic syndrome, and dyslipidemia. These conditions affect millions globally and represent a multi-billion dollar pharmaceutical market.

Insmed's lead product candidate, IKF-357, is a long-acting recombinant human IGF-1 analog, developed for treating conditions including malnutrition and metabolic disorders. While IKF-357 is not explicitly named in Patent 10,105,418, the patent's claims likely cover aspects of its composition or method of use.

The market potential hinges on demonstrating clinical efficacy and safety in target patient populations, obtaining regulatory approvals, and navigating the competitive landscape. Key competitors in the metabolic disorder space include manufacturers of GLP-1 receptor agonists, SGLT2 inhibitors, and other agents targeting insulin sensitivity and glucose control.

What are the Potential Infringement Risks?

Companies developing or marketing therapeutic agents for metabolic disorders, particularly those involving IGF-1 or molecules with similar mechanisms of action, face potential infringement risks.

• Composition of Matter Claims (e.g., Claim 22): Any entity manufacturing or selling a pharmaceutical composition containing the specific polypeptide defined by SEQ ID NO: 1, along with a pharmaceutically acceptable carrier, without a license from Insmed, would likely infringe.
• Method of Use Claims (e.g., Claim 1): Any entity inducing, assisting, or performing a method of treating a subject diagnosed with a metabolic disorder (as defined in the patent) by administering the claimed polypeptide composition, would risk infringement.

Determining infringement requires a detailed analysis of the accused product or method against the specific language of each claim, considering claim construction principles established by U.S. patent law. Independent development of similar IGF-1 analogs with different sequences or therapeutic mechanisms may mitigate infringement risk. However, the broad nature of some IGF-1 patents necessitates careful freedom-to-operate assessments.

What is the Patent's Strength and Weaknesses?

Strengths:

• Specific Polypeptide: The patent claims are directed to a specific polypeptide sequence (SEQ ID NO: 1), providing a tangible point of reference for infringement analysis.
• Therapeutic Indication: The focus on metabolic disorders, a large and growing market, enhances its commercial relevance.
• Insmed's Portfolio: The patent is part of a broader IP strategy by Insmed, suggesting a commitment to defending and leveraging this technology.

Weaknesses:

• Prior Art Challenges: The existence of prior art disclosing modified IGF-1 analogs for metabolic disorders, as evidenced by the prosecution history, could be grounds for future validity challenges.
• Specificity of Claims: While specific, the precise definition of "metabolic disorder" and the required characteristics (e.g., "elevated fasting insulin levels") can be subject to interpretation and may not cover all potential metabolic conditions.
• Enforcement Costs: Defending patent rights can be costly, and litigation outcomes are never guaranteed.

Key Takeaways

• United States Patent 10,105,418 protects specific compositions and methods for treating metabolic disorders using a modified IGF-1 polypeptide.
• The patent's claims are directed to the polypeptide SEQ ID NO: 1 and its use in treating conditions characterized by insulin resistance and dyslipidemia.
• The prior art landscape includes other disclosures of modified IGF-1 analogs for metabolic conditions, potentially impacting the patent's long-term validity.
• Insmed Incorporated holds a portfolio of related patents, indicating a strategic approach to protecting its IGF-1 technology.
• The commercial relevance is significant due to the large market for metabolic disorder treatments, though competition is high.
• Potential infringement risks exist for entities developing IGF-1 based therapies for metabolic indications.

Frequently Asked Questions

• Does U.S. Patent 10,105,418 cover all forms of IGF-1? No, the patent specifically claims compositions and methods involving a particular modified IGF-1 polypeptide sequence designated as SEQ ID NO: 1. It does not cover native IGF-1 or other IGF-1 analogs unless they fall within the defined scope of the claims.

• What specific metabolic disorders are covered by the patent? The patent covers metabolic disorders characterized by at least one of elevated fasting insulin levels, insulin resistance, or dyslipidemia. Specific conditions like type 2 diabetes or metabolic syndrome are examples that fit these characteristics.

• Can a company independently develop a therapeutic for metabolic disorders without infringing this patent? Independent development is possible if the developed product or method does not fall within the literal scope of the claims of U.S. Patent 10,105,418 or any other relevant patent. This requires a thorough freedom-to-operate analysis, considering the specific polypeptide sequence, composition, and method of treatment.

• What is the current commercial status of the technology claimed in U.S. Patent 10,105,418? While the patent itself is a legal document, its commercial status is linked to Insmed Incorporated's product development pipeline. Insmed's product candidate IKF-357 is an IGF-1 analog intended for metabolic disorders, and this patent likely supports that development.

• What are the potential implications of future patent challenges for U.S. Patent 10,105,418? If the patent is challenged on grounds of invalidity (e.g., based on prior art) and found to be invalid, its claims would no longer be enforceable. This could open up the market for competitors and reduce the exclusivity period for Insmed.

Citations

[1] Insmed Incorporated. (2018). U.S. Patent 10,105,418. Washington, DC: U.S. Patent and Trademark Office. [2] Somatogen, Inc. (2005). U.S. Patent Application Publication No. US 2005/0261178 A1. Washington, DC: U.S. Patent and Trademark Office. [3] Somatogen, Inc. (2008). U.S. Patent Application Publication No. US 2008/0108559 A1. Washington, DC: U.S. Patent and Trademark Office. [4] The General Hospital Corporation. (2008). International Patent Application Publication No. WO 2008/149042 A2. Geneva, Switzerland: World Intellectual Property Organization. [5] Insmed Incorporated. (2016). U.S. Patent 9,387,165. Washington, DC: U.S. Patent and Trademark Office. [6] Insmed Incorporated. (2017). U.S. Patent 9,707,412. Washington, DC: U.S. Patent and Trademark Office. [7] Insmed Incorporated. (2019). U.S. Patent Application Publication No. US 2019/0343757 A1. Washington, DC: U.S. Patent and Trademark Office.

Details for Patent 10,105,418

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010	10,105,418	2033-12-23
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	October 21, 2013	10,105,418	2033-12-23
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	November 19, 2018	10,105,418	2033-12-23